Immunome Rg

Clinical‑stage biotech Immunome, Inc. (Bothell, WA) focuses on targeted cancer therapies, featuring a Phase 3 Varegacestat for desmoid tumors, a Phase 1 ADC IM‑1021, and a robust preclinical radioligand and ADC portfolio.

Headquarters: United States (USA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Professional Services
Industry: Biotechnology Research

Employees: 168
HQ: Bothell

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
IMNM	Immunome Rg Cap: 2.3B	EQUITY	NMS	USD	US45257U1088	Active	📈